At Artemis Colorado we’re committed to providing the most advanced medical procedures available. We are thrilled to offer a NEW cosmetic treatment for women and men bothered by an excessive fat layer underneath their chin. Whether this “double chin” is caused by genetics, weight gain or aging, we can help.
KYBELLA® (deoxycholic acid) injection is the first and only FDA-approved injectable treatment that contours and improves the appearance of submental fullness, sometimes referred to as “double chin.”
KYBELLA® can only be administered by specially trained, certified doctors. Dr. Pinsinski is proud to have completed this training in order to provide this life-changing procedure!
The active ingredient in KYBELLA® is deoxycholic acid, a naturally-occurring molecule in the body that aids in the breakdown and absorption of dietary fat. When injected into the fat beneath your chin, KYBELLA® causes the destruction of fat cells. Once destroyed, those cells cannot store or accumulate fat.
In your free consult, we will design a customized plan to improve your chin profile. During your treatment sessions, we will administer KYBELLA® into the fat under your chin using multiple injections.
Many patients experience visible results in 2 to 4 treatment sessions. Up to 6 treatment sessions may be administered, spaced no less than one month apart. The total cost depends on how many treatments you need.
For a full disclosure of side effects, click here. Overall you can expect temporary swelling, bruising and numbness, but in 6 to 9 month, your double chin will have disappeared and be gone forever!
KYBELLA® Indication and Important Safety Information
KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.
The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.
Important Safety Information
KYBELLA® is contraindicated in the presence of infection at the injection sites.
Warnings and Precautions
Marginal Mandibular Nerve Injury
Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.
Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration-site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition.
In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.
Risk of Injecting Into or in Proximity to Vulnerable Anatomic Structures
To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1 cm-1.5 cm) to salivary glands, lymph nodes, and muscles.
The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.
Please visit www.mykybella.com for Full Prescribing Information.